Obesity is an increasingly prevalent disease regulated by genetic and environmental factors. Emerging studies indicate that immune cells, including monocytes, granulocytes and lymphocytes, regulate metabolic homeostasis and are dysregulated in obesity 1, 2 . Group 2 innate lymphoid cells (ILC2s) can regulate adaptive immunity 3, 4 and eosinophil and alternatively activated macrophage responses 5 , and were recently identified in murine white adipose tissue (WAT) 5 where they may act to limit the development of obesity 6 . However, ILC2s have not been identified in human adipose tissue, and the mechanisms by which ILC2s regulate metabolic homeostasis remain unknown. Here we identify ILC2s in human WAT and demonstrate that decreased ILC2 responses in WAT are a conserved characteristic of obesity in humans and mice. Interleukin (IL)-33 was found to be critical for the maintenance of ILC2s in WAT and in limiting adiposity in mice by increasing caloric expenditure. This was associated with recruitment of uncoupling protein 1 (UCP1) 1 beige adipocytes in WAT, a process known as beiging or browning that regulates caloric expenditure [7] [8] [9] . IL-33-induced beiging was dependent on ILC2s, and IL-33 treatment or transfer of IL-33-elicited ILC2s was sufficient to drive beiging independently of the adaptive immune system, eosinophils or IL-4 receptor signalling. We found that ILC2s produce methionine-enkephalin peptides that can act directly on adipocytes to upregulate Ucp1 expression in vitro and that promote beiging in vivo. Collectively, these studies indicate that, in addition to responding to infection or tissue damage, ILC2s can regulate adipose function and metabolic homeostasis in part via production of enkephalin peptides that elicit beiging.
Group 2 innate lymphoid cells (ILC2s) respond to the cytokine interleukin (IL)-33 (refs 3,10,11) , and both IL-33 and ILC2s have been implicated in the regulation of metabolic homeostasis in mice 5, 6, 12 . To address whether ILCs are present in human white adipose tissue (WAT) or dysregulated in obese patients, we obtained abdominal subcutaneous WAT from non-obese human donors and identified a lineage (Lin)-negative cell population that expresses CD25 (IL-2Ra) and CD127 (IL-7Ra) (Fig. 1a, Extended Data Fig. 1a ). This cell population expressed GATA binding protein 3 (GATA-3) and the IL-33 receptor (IL-33R) (Fig. 1b) , consistent with ILC2s in other human tissues 13, 14 . A Lin
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1 CD127 1 cell population that expresses GATA-3 and IL-33R was also identified in epididymal (E)-WAT of mice (Fig. 1c, d ). These cells were developmentally dependent on inhibitor of DNA binding 2 (Id2), transcription factor 7 (TCF-7) and the common gamma chain (c c ) and produced the effector cytokines IL-5 and IL-13 (Extended Data Fig. 1b-e) , similar to murine ILC2s as described previously 3, 5, 10, 11, 14, 15 . We compared ILC2 frequencies in abdominal subcutaneous WAT from non-obese versus obese donors (Extended Data Table 1 ). WAT from obese donors exhibited decreased frequencies of ILC2s compared to non-obese controls (Fig. 1e, f) . The obese group was enriched in older females compared to the non-obese group, but age and sex did not explain the difference in ILC2 frequencies between obese and non-obese donors (Extended Data Fig. 1f, g ). To test whether ILC2s in WAT are also dysregulated in murine obesity, mice were fed a control diet or high-fat diet (HFD). HFD-induced obese mice exhibited decreased frequencies and numbers of ILC2s in E-WAT compared to wild-type mice fed a control diet (Fig. 1g, h ). Together, these data suggest that decreased ILC2 populations in WAT is a conserved characteristic of obesity in mice and humans.
We employed IL-33-deficient mice to test whether endogenous IL-33 regulates ILC2 responses and the development of obesity. . 2b ). Notably, when fed a normal diet, mice lacking IL-33 gained more weight, accumulated more E-WAT and iWAT and had increased adipocyte size and whole-body adiposity compared to controls (Fig. 2d-f , Extended Data Fig. 2c ). In addition, Il33 2/2 mice exhibited dysregulated glucose homeostasis as evidenced by fasting euglycaemic hyperinsulinaemia, increased HOMA-IR index (homeostatic model assessment of insulin resistance) values and impaired glucose and insulin tolerance (Extended Data Fig. 2d-h ). Together, these results indicate that endogenous IL-33 is required to maintain normal ILC2 responses in WAT and to limit the development of spontaneous obesity.
In contrast, wild-type mice treated with recombinant murine (rm)IL-33 exhibited increased accumulation of ILC2s in E-WAT and iWAT ( Fig. 2g-i) . Although body weight did not differ between groups (Fig. 2j ), mice treated with rmIL-33 had decreased adiposity and increased lean mass compared to controls (Fig. 2k) . Remarkably, HFD-fed mice treated with rmIL-33 displayed increased E-WAT ILC2 numbers in association with decreased body weight and fat mass and improved glucose homeostasis compared to HFD-fed mice treated with PBS (Extended Data Fig. 3a-f ). These beneficial metabolic effects are consistent with studies showing a protective role for IL-33 in obesity 12 and may be related to obesity-associated pathologies such as atherosclerosis that are limited by IL-33 16 . To examine the mechanisms by which IL-33 regulates adiposity we assessed energy homeostasis in control and rmIL-33-treated mice. Treatment of mice with rmIL-33 for 7 days resulted in increased caloric expenditure compared to controls (Fig. 2l) . Food intake was unchanged following chronic rmIL-33 treatment (Fig. 2m) , and the absence of hyperphagia in the setting of increased caloric expenditure seemed to be related to decreased activity (Fig. 2n, Extended Data Fig. 4a ). However, rmIL-33 did not appear to have direct suppressive effects on food intake or activity levels (Extended Data Fig. 4b-d) . These data suggest that increased caloric expenditure following 7 days of rmIL-33 treatment could not be explained by the thermic effect of food or physical activity levels, but was regulated by other physiologic processes.
An emerging cell type that is critical for regulating caloric expenditure is the beige adipocyte (also known as brite, brown-like or inducible brown adipocyte) 7, 9, 17, 18 . These specialized adipocytes produce heat by uncoupling energy substrate oxidation from ATP synthesis 7, 17, 18 , a thermogenic process that expends calories and is dependent on uncoupling protein 1 (UCP1) 8, 17 . Previous work has linked brown and beige adipocyte function to the prevention of weight gain in mice and humans 9, [19] [20] [21] . To test whether IL-33 regulates beiging, we examined WAT morphology of Il33 1/1 versus Il33 2/2 mice. iWAT from Il33 1/1 mice exhibited unilocular white adipocytes with interspersed paucilocular beige adipocytes that have multiple small lipid droplets and increased UCP1 1 cytoplasm (Fig. 3a) . In contrast, iWAT from Il33 2/2 mice had few beige adipocytes (Fig. 3b) and increased white adipocyte size compared to controls (Fig. 3a, b, Extended Data Fig. 2c ). Expression of Ucp1 was also lower in iWAT of Il33 2/2 mice compared to controls (Fig. 3c) , suggesting that IL-33 may be a critical regulator of beiging. Consistent with this, mice treated with rmIL-33 exhibited increased UCP1
1 beige adipocytes and elevated expression of Ucp1 messenger RNA in E-WAT and iWAT (Fig. 3d-f ) compared to controls, indicating that IL-33 can promote beiging of WAT. Notably, the stimulatory effect of rmIL-33 treatment on UCP1 expression was restricted to WAT and was not observed in brown adipose tissue (BAT) (Extended Data Fig. 5a-e) .
To test whether IL-33-elicited ILC2s promote beiging, congenic CD45.1 1 ILC2s from E-WAT of IL-33-treated donor mice were sortpurified and transferred into wild-type CD45. , n 5 7) groups. g, Representative plots and frequencies of murine E-WAT ILC2s from mice fed a control diet (CD, 10% kcal fat, n 5 5) or high-fat diet (HFD, 45% kcal fat, n 5 4) for 12 weeks. h, Numbers of murine ILC2s per gram of E-WAT in mice fed a CD (n 5 8) or HFD (n 5 6) for 12 weeks. Student's t-test, *P , 0.05, **P , 0.01, ***P , 0.001. Data are shown as mean 6 standard error and are representative of 2-3 independent experiments. Sample sizes are biological replicates. 1 Lin 2 cells that lack CD3, CD5, CD19, NK1.1, CD11c, CD11b and FceRIa. c, Numbers of ILC2s in inguinal (i)WAT. d, Body weight, first 10 weeks of feeding. e, Absolute and relative E-WAT and iWAT weights. f, Body composition. g-n, Wild-type mice were treated with phosphate buffered saline (PBS, n 5 10) or recombinant murine IL-33 (12.5 mg per kg body weight per day, n 5 12) by intraperitoneal injection for 7 days. g, Frequencies and h, numbers of ILC2s in E-WAT. i, Numbers of ILC2s in iWAT. j, Body weight and k, body composition. l, Caloric expenditure over a 24-h period, days 6-to-7 of treatment. Non-shaded area, lights on. Shaded area, lights off. m, Food intake and n, total activity (beam breaks) over the 24-h period in l. Student's t-test or ANOVA with repeated measures. *P , 0.05, **P , 0.01, ***P , 0.001. Data are shown as mean 6 standard error and are representative of 2 independent experiments. Sample sizes are biological replicates.
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Data Fig. 6a ). CD45.1 1 donor ILC2s could be identified in iWAT (Fig. 3g ) and E-WAT (Extended Data Fig. 6b ) of mice that received ILC2s but not in control mice that received PBS, and total ILC2 numbers were significantly increased in iWAT of mice receiving CD45.1 1 ILC2s compared to controls (Fig. 3h) . Transferred ILC2s could not be identified in BAT, mesenteric lymph nodes or lung (Extended Data  Fig. 6b) , indicating selective accumulation of WAT-derived ILC2s in WAT of recipient mice. Transfer of ILC2s was associated with increased
UCP1
1 beige adipocytes, augmented expression of Ucp1 and elevated oxygen consumption in iWAT (Fig. 3i-k) .
To test whether IL-33 promotes beiging of WAT in an ILC2-dependent manner, we treated ILC2-deficient Rag2 2/2 cc 2/2 mice with IL-33 in the presence or absence of adoptively transferred congenic ILC2s (Extended Data Fig. 6c ). Rag2 2/2 cc 2/2 (cc is also known as Il2rg) mice supported accumulation and IL-33-induced population expansion of transferred E-WAT-derived ILC2s in host E-WAT (Fig. 3l, Extended Data Fig. 6d ). IL-33 treatment increased expression of Ucp1 in E-WAT of ILC2-sufficient Rag2 2/2 controls but not ILC2-deficient Rag2 2/2 cc 2/2 mice (Fig. 3m) . Strikingly, rmIL-33-induced increases in expression of Ucp1 and beiging were restored in ILC2-reconstituted Rag2 2/2 cc 2/2 mice (Fig. 3m, Extended Data Fig. 6e ). Collectively, these results indicate that IL-33-induced beiging of WAT requires a c c -dependent cell population and that ILC2s are sufficient to rescue this defect, suggesting that IL-33-induced beiging is critically dependent on ILC2s.
ILC2s have been shown to promote the eosinophil/IL-4Ra/alternativelyactivated macrophage (AAMac) pathway that can elicit beiging through IL-4Ra-dependent production of noradrenaline by AAMacs 5, [22] [23] [24] . In addition, regulatory T (T reg ) cells in WAT are known to be critical for regulating glucose homeostasis in mice 25 and are increased following rmIL-33 treatment (Extended Data Fig. 3g, h ). Therefore, we sought to test whether the IL-33/ILC2 pathway could promote beiging in the absence of eosinophils, IL-4Ra or the adaptive immune system. Remarkably, delivery of rmIL-33 to DblGata1 (also known as Gata1 tm6Sho ; eosinophil-deficient), Il4ra 2/2 or Rag2 2/2 mice elicited beiging of WAT ( Obesity is associated with both decreased ILC2s ( Fig. 1 ) and defective beige adipocytes 5, 9, 21 . To address whether ILC2s produce factors that could directly regulate beiging, we employed genome-wide transcriptional profiling of ILC2s versus group 3 ILCs (ILC3s) to compare gene expression enrichment scores of 69 genes previously linked to human obesity (Extended Data Table 2) 26, 27 . This analysis identified one gene, proprotein convertase subtilisin/kexin type 1 (Pcsk1) (also known as prohormone convertase 1, PC1), to be significantly enriched in ILC2s but not ILC3s ( Fig. 4a , P , 0.01). PCSK1 is an endopeptidase involved in processing some prohormones into active forms 28 , and loss-of-function mutations in both mice and humans are associated with increased susceptibility to obesity and decreased caloric expenditure 29 . The most differentially expressed PCSK1 target in ILC2s versus ILC3s was proenkephalin A (Penk) (Fig. 4b) , which encodes endogenous opioid-like peptides such as methionine-enkephalin (MetEnk). Production of MetEnk by ILC2s was confirmed by flow cytometric analysis of sort-purified ILC2s (Fig. 4c) . Following IL-33 stimulation, ILC2 production of MetEnk peptides was increased (Fig. 4d) . In vivo delivery of MetEnk peptides into wild-type mice elicited UCP1 1 beige adipocytes, upregulated expression of Ucp1 and increased oxygen consumption in iWAT ( Fig. 4e-g ), indicating the formation of functional beige fat. Consistent with this, MetEnk treatment decreased iWAT mass (Fig. 4h ). These changes were not associated with increased expression of Il4 or Il13 (Fig. 4i) or altered eosinophil or AAMac numbers in iWAT (Fig. 4j) .
Gene expression analyses in wild-type mice at steady state indicated that Il33 and Penk expression levels were increased in iWAT compared to BAT (Fig. 4k ). In addition, expression of the MetEnk receptor d1 opioid receptor (Oprd1) was higher in iWAT compared to BAT, whereas expression of the other known MetEnk receptor Opioid growth factor receptor (Ogfr) was lower in iWAT compared to BAT (Fig. 4l) , suggesting that there may be tissue-specific effects of MetEnk in iWAT compared to BAT. Consistent with this, MetEnk stimulation induced a-c, Il33 1/1 (n 5 6) or Il33 2/2 (n 5 5) mice were fed a low-fat diet (10% kcal fat) for 12 weeks starting at age 7 weeks. Uncoupling protein 1 (UCP1) immunohistochemistry (IHC) in iWAT from a, Il33 1/1 or b, Il33 2/2 mice. Scale bars, 100 mm. c, Ucp1 transcript levels in iWAT. d-f, Wild-type mice were treated with PBS or recombinant murine IL-33 (12.5 mg per kg body weight per day) by intraperitoneal injection for 7 days. d, E-WAT and e, iWAT UCP1 IHC. Scale bars, 100 mm. f, Ucp1 transcript levels in E-WAT and iWAT. g-k, Sort-purified CD45.1 1 ILC2s ( 310 5 ) from E-WAT of IL-33-treated mice were transferred into 12-week-old CD45.2 1 wild-type recipients by subcutaneous and intraperitoneal injection daily for 4 days (PBS, n 5 8; ILC2, n 5 8 except panel k). g, Representative plots identifying donor and recipient ILC2s. Plots pre-gated on live CD45
1 Lin 2 CD25 1 IL33R 1 cells. Lineage cocktail: CD3, CD5, CD19, NK1.1, CD11c, CD11b and FceRIa. h, Total numbers of ILC2s per gram iWAT. i, iWAT UCP1 IHC. Scale bars, 100 mm. j, Ucp1 expression in iWAT. k, iWAT oxygen consumption. PBS, n 5 14; ILC2, n 5 15. l, m, Sort-purified congenic CD45.1 1 ILC2s ( 310 5 ) from E-WAT of IL-33-treated mice were transferred into Rag2 2/2 cc 2/2 mice once by intraperitoneal injection. ILC2-sufficient Rag2 2/2 mice, ILC2-deficient Rag2 2/2 cc 2/2 mice and ILC2-reconstituted Rag2 2/2 cc 2/2 mice were treated with PBS or recombinant murine IL-33 (12.5 mg per kg body weight per day) by intraperitoneal injection for 7 days (n 5 4 mice per group). l, ILC2 numbers per gram E-WAT. m, Ucp1 expression in E-WAT. Student's t-test or two-way ANOVA. *P , 0.05, **P , 0.01, ***P , 0.001. Data are shown as mean 6 standard error and are representative of 2-4 independent experiments. Sample sizes are biological replicates.
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Ucp1 expression in cultured primary adipocytes from iWAT ( Fig. 4m) but not BAT (Fig. 4n) . Taken together, these results identify that ILC2s express MetEnk that can directly promote beiging of WAT (Extended Data Fig. 8 ).
To our knowledge, these data collectively provide the first demonstration that dysregulated ILC2 responses in WAT are a conserved feature of obesity in humans and mice and that the IL-33/ILC2 axis regulates metabolic homeostasis by eliciting beiging of white adipose tissue. Production of enkephalin peptides is a previously unrecognized effector mechanism employed by ILC2s to regulate metabolic homeostasis. From an evolutionary perspective, coupling ILC2-dependent innate immune effector functions with the maintenance of systemic metabolic homeostasis could provide a rapid, integrated multi-organ response that allows mammals to surmount multiple environmental challenges including infection, nutrient stress or changes in temperature. Given that impaired beige adipocyte function is associated with increased weight gain and obesity in mice 9, 19 and that activity of brown/beige 17,30 adipose tissue is dysregulated in obese patients 20, 21 , targeting the IL-33/ILC2/beiging pathway could represent a new approach for treating obesity and obesityassociated diseases.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. ) for 4 days. Isotype control MFI for each group was subtracted before calculating relative expression. Shown are averages from 4 independent experiments, each representing pooled cells from n 5 3-5 mice and measured in duplicate or triplicate. e-j, Wild-type mice were treated with PBS (n 5 7) or MetEnk (n 5 9) by subcutaneous injection (10 mg per kg body weight per day) for 5 days. e, Uncoupling protein 1 (UCP1) immunohistochemistry (IHC) in inguinal white adipose tissue (iWAT) ) per gram of iWAT. k, Il33 and Penk mRNA and l, Ogfr and Oprd1 mRNA in iWAT versus brown adipose tissue (BAT), n 5 8. m, n, Stromal vascular fraction (SVF) cells from m, iWAT or n, BAT of 4-week-old C57BL/6 mice were differentiated into primary adipocytes for 2 days, treated with PBS or 50 mM MetEnk from days 2-8 and harvested on day 8 (iWAT: n 5 7 PBS, n 5 8 MetEnk; BAT: n 5 6 PBS, n 5 6 MetEnk). Student's t-test or ANOVA, *P , 0.05, ***P , 0.001. Data are shown as mean 6 standard error and are representative of 2-3 independent experiments. Sample sizes are biological replicates. 2/2 mice 15 were generated as described previously. Unless otherwise noted, all mice were on a C57BL/6 background. All mice were males and had ad libitum access to food and water and were maintained in a specific-pathogen free facility with a 12 h:12 h light:dark cycle. Animals were randomly assigned to groups of n 5 3-5 mice per group per experiment, and at least two independent experiments were performed throughout. In all in vivo experiments, a single technical replicate per mouse was performed except in glucose homeostasis tests described below, in which 2-4 technical replicates were performed per mouse for each time point. For all mRNA analyses, biological replicates were measured in duplicate or triplicate. For all in vitro experiments, 2-3 technical replicates were performed in each independent experiment. Sample sizes in each independent experiment were selected to have power of at least 90% using published sample size/power formulas Table 1 . NYODN samples were from recently deceased organ donors at the time of organ acquisition for clinical transplantation through an approved research protocol and MTA with the NYODN. All NYODN donors were free of cancer and were hepatitis B, hepatitis C and human immunodeficiency virus-negative. Tissues were collected after the donor organs were flushed with cold preservation solution and clinical procurement process was completed. Samples from CHTN were collected from non-deceased adults undergoing panniculectomies, and were harvested from discarded connective tissue by CHTN staff. . There were no differences in the proportion of donors from NYODN or CHTN between non-obese and obese groups (Extended Data Table 1 ). ILC2 frequencies were also compared for all characteristics shown in Extended Data Table 1 , and those characteristics that had a P value , 0.10 were interrogated to test whether they could explain the differences in ILC2 frequencies observed between non-obese versus obese donors. The human samples from NYODN do not qualify as 'human subjects' research, as confirmed by the Columbia University IRB, and the human samples from CHTN were de-identified and were not obtained for the specific purpose of these studies and therefore are not considered 'human subjects' research. Diet-induced obesity. Where indicated, mice were fed a control diet (CD, 10% kcal fat, Research Diets, New Brunswick, New Jersey) or high fat diet (HFD, 45% or 60% kcal fat as indicated, Research Diets) for the indicated period of time starting at 6-8 weeks of age. CD and HFD were gamma-irradiated (10-20 kGy). In all experiments that did not employ HFD or CD, mice were fed a standard autoclavable rodent chow (5% kcal fat, 5010, Lab Diets, St. Louis, Missouri). In vivo cytokine and enkephalin peptide treatments. Mice were administered 12.5 mg per kg body weight carrier-free recombinant murine IL-33 (rmIL-33, R&D Systems, Minneapolis, Minnesota) in sterile phosphate buffered saline (PBS) by intraperitoneal (i.p.) injection for 7 days at the indicated dose. In HFD studies, mice were treated with 12.5 mg per kg body weight recombinant murine IL-33 or PBS once every 4 days by i.p. injection. In some studies, mice were treated with a previously reported 32 dose of 10 mg per kg body weight [Met 5 ]-enkephalin acetate salt hydrate (MetEnk, amino acid sequence YGGFM, $ 95.0% purity by HPLC, Sigma Aldrich, St. Louis, MO) in PBS or with PBS alone by bilateral subcutaneous injection near the iWAT daily for 5 days (approximately 200 ml per side). MetEnk or vehicle injections were performed under isoflurane anaesthesia. Sort-purification and transfer of ILC2s. E-WAT was harvested from male CD45.1 1 C57BL/6 mice that received daily injections of rmIL-33 (12.5 mg per kg body weight) for 7 days by intraperitoneal injection. Live CD45
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1 Lin 2 CD25 1 IL-33R 1 ILC2s were sort-purified using an Aria Cell Sorter (BD) to $ 98% purity, and 10 5 ILC2s were immediately transferred to the indicated recipient mice by intraperitoneal injection (5 3 10 4 cells) and by subcutaneous injection near iWAT (5 3 10 4 cells split evenly for bilateral injections). Daily transfers were performed for 4 consecutive days, and tissues were harvested on day 5. In ILC2 reconstitution experiments involving Rag2 2/2 cc 2/2 recipient mice, 10 5 ILC2s were transferred by a single intraperitoneal injection, and the next day mice were treated with PBS or rmIL-33 (12.5 mg per kg body weight) by daily intraperitoneal injection for 7 days.
In vivo metabolic phenotyping. Mice were single-housed in an OxyMax Comprehensive Laboratory Animal Monitoring System (CLAMS, Columbus Instruments, Columbus, Ohio) for 24 h. Mice were acclimated to the CLAMS cages for 24 h before measurements commenced. Fat mass and adiposity were measured by 1 H-nuclear magnetic resonance (NMR) spectroscopy. For glucose tolerance tests, mice were fasted overnight for 14-16 h and injected with 2 g per kg body weight D-glucose by i.p. injection. Blood glucose values were measured just before injection (time 0) and at 20, 40, 60, 90 and 120 min post-injection. For insulin tolerance tests, mice were fasted for 4-6 h and then injected with bovine insulin (0.5 U per kg body weight). Blood glucose values were measured just before injection (time 0) and at 20, 40 and 60 min post-injection. To measure fasting blood glucose and insulin concentrations, mice were fasted overnight for 14-16 h, and blood glucose values were measured followed by collection of approximately 20-30 ml blood for serum insulin concentration determination using the Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem). Homeostatic model assessment of insulin resistance (HOMA-IR) index values were calculated as described previously 33 . All blood glucose measurements were performed using FreeStyle Lite handheld glucometer (Abbot) in duplicate or triplicate. Histologic analysis. Tissues were fixed in 4% paraformaldehyde in PBS for at least 48 h at 4 uC and embedded in paraffin before cutting 5-mm sections and staining with haematoxylin and eosin (H&E) or performing immunohistochemistry (IHC) with rabbit anti-UCP1 antibody (Abcam, ab10983). For IHC, rehydrated sections were microwaved in 10 mM citric acid buffer (pH 6.0) for antigen retrieval, and endogenous peroxidases were quenched with 3% hydrogen peroxide. Sections were blocked with Avidin D, biotin and protein blocking agent in sequential order followed by application of the anti-UCP1 antibody (1:500). A biotinylated anti-rabbit antibody was used as a secondary antibody. Horseradish peroxidase-conjugated ABC reagent was applied, and then DAB reagent was used to develop the signal before counterstaining in haematoxylin and dehydrating the sections in preparation for mounting. Stained sections were visualized and photographed using a Nikon E600 bright field microscope. Adipocyte area quantification. Inguinal white adipose tissue (iWAT) sections were H&E stained and imaged at 340 magnification. White adipocyte area was calculated using ImageJ software by drawing ellipses circumscribing white adipocytes. The scale was set to 8 pixels per mm based on the pixel length of a 100-mm scale bar at 340 magnification. Two to three images, each from a different area of a given sample, were captured per animal. , MN) ; CD206-Alexa Fluor 647 (MR5D3) from AbD Serotec (Raleigh, NC); and Streptavidin-APC from eBioscience. Foxp3, GATA-3 and CD206 staining was performed following fixation and permeabilization with the Foxp3 Staining Buffer Set (eBioscience). Human cells were stained with anti-human GATA-3-PE (TWAJ), TCRab-PerCPCy5.5 (IP26), CD5-PerCP-Cyanin5.5 (L17F12), CD19-Alexa Fluor 700 (HIB19), CD11c-Alexa Fluor 700 (3.9), CD127-eFluor 780 (eBioRDR5), CD45-eFluor 605NC (HI30), FceRIa-biotin (AER-37) and Streptavidin-eFluor 650NC from eBioscience; CD56-Alexa Fluor 700 (B159), CD16 (3G8), CD3 (SP34-2) and CD25-PE-Cy7 (M-A251) from BD Pharmingen; CD11b-PE-Texas Red (M1/70.15) from Life Technologies; and ST2L-FITC from MD Bioproducts. Stained cells were acquired on a BD LSRII flow cytometer (BD Biosciences), and data were analysed using FlowJo software version 9.6.4 (Tree Star, Inc.). Intracellular cytokine analysis. To examine ILC2 effector cytokine production, single-cell suspensions of E-WAT or iWAT SVF were stimulated for 4 h ex vivo with phorbol 12-myristate 13-acetate (PMA) (100 ng ml
21
) and ionomycin (1 ng ml
) in the presence of brefeldin A (10 mg ml 21 ) (all from Sigma-Aldrich) in a 37 uC incubator LETTER RESEARCH (5% CO 2 ). Cells were then surface-stained, fixed and permeabilized using Cyto Fix/Perm (BD Pharmingen) according to manufacturer's instructions before intracellular staining for IL-5 (APC-IL-5, clone TRFK5, eBioscience) and IL-13 (PE-IL-13, eBio13A, eBioscience). Monensin (1:1500) was also used for intracellular staining with rabbit anti-mouse MetEnk (bs-1759R, Bioss USA, Woburn, MA) or rabbit antimouse IgG (Isotype control, Bioss USA) followed by staining with goat anti-rabbit PE (sc-3739, Santa Cruz Biotechnology, Dallas, TX). Real-time PCR. Adipose tissues were snap-frozen in TRIzol (Invitrogen) and homogenized using a Tissue Lyser (Qiagen). RNA was isolated from the aqueous phase using the RNeasy kit (Qiagen) in accordance with the manufacturer's instructions. cDNA was synthesized from 1.0 mg RNA using Superscript II Reverse Transcriptase (Invitrogen) and oligo(dT) (Invitrogen). Real-time PCR was performed using SYBR Green technology (Applied Biosystems) with previously published primer sequences for murine Ucp1 17 and Qiagen QuantiTect real-time PCR primers for b-actin, Il33, Penk, Oprd1 and Ogfr. Reactions were run on the 7500 Fast Real-Time PCR System (Applied Biosystems) or the QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems). Results were normalized to the housekeeping gene b-actin, and the DDC t method was employed for all real-time PCR analyses. Microarrays and ILC2 versus ILC3 gene enrichment analyses. Microarray analyses (,25,000 genes) were performed using previously published microarray data sets (GEO GSE46468) 14 . 
CD4
1 ILC3s from the spleen (4 biological replicates each comprising 10 pooled spleens) were sorted using a FACS Aria (BD) directly into TRIzol LS (Invitrogen) at a purity of .97% (1.5-2.0 3 10 4 cells per replicate). mRNA was isolated, amplified, labelled and hybridized to Affymetrix GeneChip (Mouse Gene 1.0 ST) as described previously 14 . Gene expression Z-scores were calculated for each of 69 obesity-associated genes in ILC2s or ILC3s (see Extended Data Table 2 for a complete list of genes). Genes that were significantly enriched compared to the average gene expression level of the entire microarray data set) in one cell population (Z . 2.20) but not the other were considered to be differentially enriched in that cell population. Bonferroni correction (alpha 5 0.05, k 5 69) was applied for microarray analyses to account for multiple testing. Tissue oxygen consumption. A ,20 mg biopsy of iWAT was isolated from directly below the lymph node and minced in PBS containing 2% BSA, 1.1 mM sodium pyruvate and 25 mM glucose. Samples were placed in an MT200A Respirometer Cell (Strathkelvin), and oxygen consumption was measured for approximately 5 min. Oxygen consumption rates were normalized to minced tissue weight. Primary adipocyte culture. iWAT or BAT was dissected from 4 week-old C57BL/ 6 mice (n 5 5 per experiment, pooled) and digested as described above. Stromal vascular fraction (SVF) cells were plated in 12-well CellBind plates, and adherent cells were grown to confluence. Cells were differentiated into adipocytes as previously described 34 . Briefly, cells were cultured for 2 days with 850 nM insulin, 1 nM 3,39,5-triiodo-L-thyronine (T 3 ), 1 mM rosiglitazone, 125 nM indomethacin (125 mM for BAT primary adipocytes), 0.5 mM isobutylmethylxanthine (IBMX) and 1 mM dexamethasone in adipocyte culture media (DMEM:F12 [50:50] supplemented with 10% heat-inactivated FBS, penicillin, streptomycin and L-glutamine). Cells were then maintained in adipocyte culture media supplemented with 850 nM insulin and 1 nM T 3 with either PBS or 50 mM MetEnk for 6 days, with fresh media replacement every 2 days. Cells were harvested on day 8 in TRIzol. Statistical analyses. Data are expressed as mean 6 standard error of the mean (s.e.m.). Statistical significance was determined for normally-distributed data by using the two-tailed Student's t test or a one-way or two-way analysis of variance (ANOVA) followed by Sidak or Tukey post-hoc tests. If variance differed between groups, the appropriate statistical correction was applied (for example, Welch's correction). Correlation analyses were conducted using Pearson linear regression. Proportions among human samples were compared by Chi-squared tests. Significance was set at P , 0.05. Statistical analyses were performed with Prism 6 (GraphPad Software, Inc.) or SPSS Statistics version 22 (IBM). 1 cells were pre-gated, and IL-5 and IL-13 protein levels were assessed. Plot shown is representative of n 5 12 mice from 3 independent experiments. f, Human WAT ILC2 frequencies were compared in the 7 youngest donors (36.0 6 3.5 years old) versus the 7 oldest donors (55.9 6 1.9 years old). For panels a-f, groups were compared using Student's t-test, *P , 0.05, ***P , 0.001. For panels g-h, a two-way ANOVA with repeated measures was performed followed by Tukey post-hoc test. *P , 0.05, **P , 0.01, ***P , 0.001. Data shown are from a single cohort and are representative of 2 independent experiment. Sample sizes are biological replicates. LETTER RESEARCH
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